@prefix dcterms: <http://purl.org/dc/terms/> .
@prefix this: <http://bio2rdf.org/drugbank_resource:DB00502_DB00564_nanopub.RAGLgTimqKobkRcKUSxxGZ_Y_xlB0scTed9KWYPseAnOw> .
@prefix sub: <http://bio2rdf.org/drugbank_resource:DB00502_DB00564_nanopub.RAGLgTimqKobkRcKUSxxGZ_Y_xlB0scTed9KWYPseAnOw#> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix pav: <http://purl.org/pav/> .
@prefix orcid: <http://orcid.org/> .
@prefix codebase: <https://github.com/tkuhn/bio2rdf2nanopub> .
@prefix version: <https://github.com/tkuhn/bio2rdf2nanopub/tree/eda7951a5f6c622c5d2132f50c3093138484a349> .
@prefix instance: <https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB> .
@prefix process: <https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB.3c184e6c-ceb8-4275-a679-71dfbdac2a11> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix has-source: <http://semanticscience.org/resource/SIO_000253> .
@prefix d: <http://bio2rdf.org/drugbank:> .
@prefix dv: <http://bio2rdf.org/drugbank_vocabulary:> .
@prefix dr: <http://bio2rdf.org/drugbank_resource:> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:publicationInfo;
    a np:Nanopublication .
}

sub:assertion {
  d:DB00502 dv:ddi-interactor-in dr:DB00502_DB00564 .
  
  d:DB00564 dv:ddi-interactor-in dr:DB00502_DB00564 .
  
  dr:DB00502_DB00564 dcterms:identifier "drugbank_resource:DB00502_DB00564";
    dcterms:title "DDI between Haloperidol and Carbamazepine - Carbamazepine may decrease the serum concentration of haloperidol by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of haloperidol if carbamazepine is initiated, discontinued or dose changed."@en;
    a dv:Drug-Drug-Interaction;
    rdfs:label "DDI between Haloperidol and Carbamazepine - Carbamazepine may decrease the serum concentration of haloperidol by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of haloperidol if carbamazepine is initiated, discontinued or dose changed. [drugbank_resource:DB00502_DB00564]"@en .
}

sub:provenance {
  sub:assertion has-source: dr:bio2rdf.dataset.drugbank.R3 .
}

sub:publicationInfo {
  sub:signature.MCwCFHQS_6zzLiZ7 npx:hasPublicKey "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";
    npx:hasSignature "MCwCFHQS/6zzLiZ7PDDfghxD0VvFdOVTAhR7AofTDw2iJoeljBue+yogRBEmIA==";
    npx:signedBy instance: .
  
  this: dcterms:created "2018-03-30T11:12:29.548+02:00"^^xsd:dateTime;
    dcterms:license <https://creativecommons.org/licenses/by-nc/4.0/>;
    npx:hasSignatureElement sub:signature.MCwCFHQS_6zzLiZ7;
    prov:wasGeneratedBy process: .
  
  instance: prov:specializationOf codebase:;
    prov:wasAttributedTo orcid:0000-0002-1267-0234 .
  
  process: dcterms:identifier "3c184e6c-ceb8-4275-a679-71dfbdac2a11";
    prov:used version:;
    prov:wasAssociatedWith instance:;
    prov:wasStartedBy orcid:0000-0002-1267-0234 .
  
  version: dcterms:isVersionOf codebase:;
    pav:version "eda7951a5f6c622c5d2132f50c3093138484a349";
    prov:wasAttributedTo orcid:0000-0002-1267-0234 .
}